<H1>Chapter DOI: 10.1208/aapsj070353<br/>Cited-By Count: 18</H1><table border="1" width="30%"><tr><td>Total References</td><td>16</td></tr><tr><td>Springer references</td><td>3</td></tr><tr><td>Non Springer references</td><td>13</td></tr><tr><td>BibStructured Count</td><td width="10%">14</td></tr><tr><td>BibUnstructured Count</td><td width="10%">2</td></tr><tr><td>DOI already available in SpringerLink</td><td>9</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol</Emphasis>. 2000;40:67&#8211;95.</td><td><a href=http://dx.doi.org/10.1146/annurev.pharmtox.40.1.67>10.1146/annurev.pharmtox.40.1.67</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Gobburu JV, Marroum PJ. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 2001;40:883&#8211;892.</td><td><a href=http://dx.doi.org/10.2165/00003088-200140120-00001>10.2165/00003088-200140120-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Holford</span> <span style='background:#DDDDDD'>NHG</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hale</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ko</span> <span style='background:#DDDDDD'>HS</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Steimer</span> <span style='background:#DDDDDD'>JL</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Sheiner</span> <span style='background:#DDDDDD'>LB.</span></span></aug>, <span style='background:#FFD9B3'>Simulation in Drug development: good practices</span>. <i>Center for Drug Development Science</i>. Available at: <span style='background:#FF3300'>http://cdds.georgetown.edu</span>. Accessed January 1, <span style='background:#66FF66'>2004</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2001;28:231&#8211;252.</td><td><a href=http://dx.doi.org/10.1023/A:1011527125570>10.1023/A:1011527125570</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>FDA.</span> <span style='background:#BCBCBC'>Guidance</span></span></aug>: <span style='background:#FFD9B3'>Population Pharmacokinetics</span>. <i>FDA guidance page</i>. Available <span style='background:#FF3300'>at:http://www.fda.gov/cder/guidance</span>. Accessed January 13, <span style='background:#66FF66'>2004</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Rubin D. Bayesianly justifiable and relevant frequency calculations for the applied statisitcian.<Emphasis Type="Italic">Ann Stat</Emphasis>. 1984;12:1151&#8211;1172.</td><td><a href=http://dx.doi.org/10.1214/aos/1176346785>10.1214/aos/1176346785</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibChapter</td><td>Gelman A, Carlin JB, Stern HS, Rubin DB. Model checking and sensitivity analysis. In: Gelman A, ed.<Emphasis Type="Italic">Bayesian Data Analysis</Emphasis>. London: Chapman &amp; Hall; 1995;161&#8211;189.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibChapter</td><td>Gelman A, Meng XL. Model checking and model improvement. In: Gilks WR, Richardson S, Spiegelhalter DJ, eds.<Emphasis Type="Italic">Markov Chain and Monte Carlo in Practice</Emphasis>. London: Chapman &amp; Hall; 1996:189&#8211;202.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2001;28:171&#8211;192.</td><td><a href=http://dx.doi.org/10.1023/A:1011555016423>10.1023/A:1011555016423</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Gelman A, Meng XL, Stern HS. Posterior predictive assessment of model fitness via realized discrepancies.<Emphasis Type="Italic">Statistica Sinica</Emphasis>. 1996;6:733&#8211;807.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Guttman I. The use of a concept of a future observation in the goodness-of-fit problems.<Emphasis Type="Italic">J R Statist Soc B</Emphasis>. 1967;1:83&#8211;100.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Tiao GC, Xu D. Robustness of maximum likelihood estimates for multi-step predictions: the exponential smoothing case.<Emphasis Type="Italic">Biometrika</Emphasis>. 1993;80:623&#8211;641.</td><td><a href=http://dx.doi.org/10.1093/biomet/80.3.623>10.1093/biomet/80.3.623</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Gelman A, Goegebeur Y, Tuerlinckx F, Van Mechelen I. Diagnostic checks for discrete data regression models using posterior predictive simulations.<Emphasis Type="Italic">J Royal Stat Soc: C</Emphasis>. 2000;49:247&#8211;268.</td><td><a href=http://dx.doi.org/10.1111/1467-9876.00190>10.1111/1467-9876.00190</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Duffull SB, Aarons L. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers.<Emphasis Type="Italic">Eur J Pharm Sci</Emphasis>. 2000;10:275&#8211;284.</td><td><a href=http://dx.doi.org/10.1016/S0928-0987(00)00085-3>10.1016/S0928-0987(00)00085-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Duffull SB, Chabaud S, Nony P, Laveille C, Girard P, Aarons L. A pharmacokinetic simulation model for ivabradine in healthy volunteers.<Emphasis Type="Italic">Eur J Pharm Sci.</Emphasis>. 2000;10:285&#8211;294.</td><td><a href=http://dx.doi.org/10.1016/S0928-0987(00)00086-5>10.1016/S0928-0987(00)00086-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Friberg LE, Freijs A, Sandstrom M, Karlsson MO. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2000;295:734&#8211;740.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>